Emerging Opportunities with Cannabinoids
| Product Code | ESP00567 |
| Publication Date | September 2008 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 74 |
| ISBN Number | 978-1-85822-328-5 |
Emerging Opportunities with Cannabinoids
This invaluable briefing provides a critical and far-reaching examination of current cannabinoid products and areas of unmet clinical need where the use of cannabinoids could be clinically beneficial and commercially profitable.
Contents
- Cannabinoid agonists and CB1 specific agonists in development
- Market size and growth
- Growth drivers and market risks
- Current and future drug therapies
- Market size and growth
- Population forecasts
- HIV/AIDS cachexia:
- Forecast number of patients with cachexia associated with HIV/AIDS ('000s)
- Cancer cachexia:
- HIV/AIDS cachexia:
- Cancer cachexia:
- HIV/AIDS cachexia:
- Cancer cachexia:
- Market size and growth
- Neuropathic pain:
- Population forecasts
- Growth drivers and market risks
- Current and future drug therapies
- CB2 agonists in development
- Market size and growth
- Population forecasts
- Forecast number of patients with osteoarthritis (millions)
- CB1 antagonists in development
- Increasing prevalence of obesity in the US
- Rates of obesity in five major European countries
- Forecast number of obese adults in millions
- Market size and growth
- Trends in per capita cigarette consumption
- Forecast number of smokers (in millions) in major developed markets
- Current and future agents
- FAAH inhibitors in development
- Acomplia (rimonabant)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Acomplia sales by use (US$ millions):
- Competitor ratio analysis
- taranabant (MK 0364)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast taranabant sales by use (US$ millions):
- Competitor ratio analysis
- otenabant (CP-945,598)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast otenabant sales by use (US$ millions):
- Competitor ratio analysis
- ibipinabant (BMS-646256; SLV-319)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast ibipinabant sales by use (US$ millions):
- Competitor ratio analysis
- surinabant (SR-147778)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Marinol (dronabinol)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Marinol Dose: Response Frequency and Adverse Experiences*
- (N = 750 treatment courses)
- Cachexia in A IDS patients:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Marinol sales by use (US$ millions):
- Competitor ratio analysis
- Cesamet (nabilone)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Cesamet sales by use (US$ millions):
- Competitor ratio analysis
- Sativex (tetrahydrocannabinol and cannabidiol)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sativex development overview
- Sales forecasts and assumptions
- Forecast Sativex sales by use (US$ millions):
- Competitor ratio analysis
- cannabinor (PRS-211,375)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Methodology
- Overview
- Cannabinoid agonists
- CRA for cannabinoid agonists
- CB1 antagonists
- CRA for CB1 antagonists
- Cannabinoids on the market and in development